247 related articles for article (PubMed ID: 22173052)
1. Proteinase-activated receptor-2 is required for normal osteoblast and osteoclast differentiation during skeletal growth and repair.
Georgy SR; Pagel CN; Ghasem-Zadeh A; Zebaze RM; Pike RN; Sims NA; Mackie EJ
Bone; 2012 Mar; 50(3):704-12. PubMed ID: 22173052
[TBL] [Abstract][Full Text] [Related]
2. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation.
Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ
J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840
[TBL] [Abstract][Full Text] [Related]
3. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
4. Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function.
Furlan F; Galbiati C; Jorgensen NR; Jensen JE; Mrak E; Rubinacci A; Talotta F; Verde P; Blasi F
J Bone Miner Res; 2007 Sep; 22(9):1387-96. PubMed ID: 17539736
[TBL] [Abstract][Full Text] [Related]
5. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
6. IL-1 plays an important role in the bone metabolism under physiological conditions.
Lee YM; Fujikado N; Manaka H; Yasuda H; Iwakura Y
Int Immunol; 2010 Oct; 22(10):805-16. PubMed ID: 20679512
[TBL] [Abstract][Full Text] [Related]
7. Proteinase-activated receptor-2 (PAR2) and mouse osteoblasts: regulation of cell function and lack of specificity of PAR2-activating peptides.
Georgy SR; Pagel CN; Wong DM; Sivagurunathan S; Loh LH; Myers DE; Hollenberg MD; Pike RN; Mackie EJ
Clin Exp Pharmacol Physiol; 2010 Mar; 37(3):328-36. PubMed ID: 19769607
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro.
Balani D; Aeberli D; Hofstetter W; Seitz M
Arthritis Rheum; 2013 Feb; 65(2):436-46. PubMed ID: 23124514
[TBL] [Abstract][Full Text] [Related]
9. Biglycan deficiency increases osteoclast differentiation and activity due to defective osteoblasts.
Bi Y; Nielsen KL; Kilts TM; Yoon A; A Karsdal M; Wimer HF; Greenfield EM; Heegaard AM; Young MF
Bone; 2006 Jun; 38(6):778-86. PubMed ID: 16364709
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro.
Saleh H; Eeles D; Hodge JM; Nicholson GC; Gu R; Pompolo S; Gillespie MT; Quinn JM
Endocrinology; 2011 May; 152(5):1911-22. PubMed ID: 21363931
[TBL] [Abstract][Full Text] [Related]
11. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
12. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
13. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.
Liu F; Lee SK; Adams DJ; Gronowicz GA; Kream BE
Bone; 2007 Apr; 40(4):1135-43. PubMed ID: 17275432
[TBL] [Abstract][Full Text] [Related]
14. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis.
Xing L; Bushnell TP; Carlson L; Tai Z; Tondravi M; Siebenlist U; Young F; Boyce BF
J Bone Miner Res; 2002 Jul; 17(7):1200-10. PubMed ID: 12096833
[TBL] [Abstract][Full Text] [Related]
15. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
16. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
17. Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.
Choudhary S; Goetjen A; Estus T; Jacome-Galarza CE; Aguila HL; Lorenzo J; Pilbeam C
J Biol Chem; 2016 Feb; 291(8):3882-94. PubMed ID: 26703472
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis.
Lee SK; Kalinowski JF; Jastrzebski SL; Puddington L; Lorenzo JA
Endocrinology; 2003 Aug; 144(8):3524-31. PubMed ID: 12865334
[TBL] [Abstract][Full Text] [Related]
19. Thrombin inhibits osteoclast differentiation through a non-proteolytic mechanism.
Sivagurunathan S; Pagel CN; Loh LH; Wijeyewickrema LC; Pike RN; Mackie EJ
J Mol Endocrinol; 2013 Jun; 50(3):347-59. PubMed ID: 23419317
[TBL] [Abstract][Full Text] [Related]
20. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
